Franklin Exponential Data ETF (BATS: XDAT)

Latest news for Franklin Exponential Data ETF (BATS:XDAT)

Technology

Communication Services

Real Estate

Financial Services

Healthcare

Industrials

Under normal market conditions, the fund invests at least 80% of its net assets in equity securities of companies that are relevant to the fund's investment theme of exponential data. It invests predominantly in common stock. In pursuing the fund's investment theme, the investment manager may invest in companies in any economic sector or of any market capitalization and may invest in companies both inside and outside of the United States, including those in developing or emerging markets. The fund is non-diversified.

Microsoft Corp

Servicenow, Inc.

Palo Alto Networks Inc.

Fair Isaac Corp

Alphabet Inc.Class A

Datadog Inc. Class A

Arista Networks Inc.

Meta Platforms, Inc.

Crowdstrike Holdings Inc. Class A

Mongodb, Inc.

Franklin Exponential Data ETF

ServiceNow

Equities

Large Cap

News

XDAT

ServiceNow investing $1.5B in UK over 5 years to expand office space, workforce, AI skills programs, reaffirming commitment.

ServiceNow Commits $1.5B To UK AI And Workforce Growth

ServiceNow NOW

Markets

Movers

Tech

General

WDAY

ServiceNow&#39;s stock is rising significantly in premarket trading after beating earnings expectations, amid leadership changes and strategic acquisitions.

Why ServiceNow Shares Are Rising Today

Carvana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>) reported quarterly earnings of $0.56 per share which beat the analyst consensus estimate of $0.21 by 166.67 percent. This is a 156 percent increase over losses of $(1.00) per share from the same period last year. The company reported quarterly sales of $3.55 billion which beat the analyst consensus estimate of $3.31 billion by 7.03 percent. This is a 46.33 percent increase over sales of $2.42 billion the same period last year.

Earnings

Earnings Beats

CVNA

Carvana Q4 EPS $0.56 Beats $0.21 Estimate, Sales $3.55B Beat $3.31B Estimate

Clearwater Analytics Hldg (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CWAN#NYSE">CWAN</a>) reported quarterly earnings of $0.13 per share which beat the analyst consensus estimate of $0.11 by 18.18 percent. This is a 30 percent increase over earnings of $0.10 per share from the same period last year. The company reported quarterly sales of $126.456 million which beat the analyst consensus estimate of $120.300 million by 5.12 percent. This is a 27.71 percent increase over sales of $99.019 million the same period last year.

CWAN

Clearwater Analytics Hldg Q4 2024 Adj. EPS $0.13 Beats $0.11 Estimate, Sales $126.456M Beat $120.300M Estimate

Texas Pacific Land Q4 2024 GAAP EPS $5.14 Up From $4.91 YoY, Sales $185.800M Beat $185.000M Estimate

Biomarin Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) reported quarterly earnings of $0.92 per share which beat the analyst consensus estimate of $0.53 by 73.58 percent. This is a 87.76 percent increase over earnings of $0.49 per share from the same period last year. The company reported quarterly sales of $747.00 million which beat the analyst consensus estimate of $713.44 million by 4.70 percent. This is a 15.60 percent increase over sales of $646.21 million the same period last year.

BMRN

Biomarin Pharmaceutical Q4 Adj $0.92 Beats $0.53 Estimate, Sales $747.00M Beat $713.44M Estimate

Enovix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENVX#NASDAQ">ENVX</a>) is looking for Q1 GAAP EPS of $(0.29)-$(0.23) vs $(0.31) analyst estimate..

Guidance

ENVX

Enovix Sees Q1 GAAP EPS $(0.29)-$(0.23) vs $(0.31) Est

Murphy USA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MUSA#NYSE">MUSA</a>) has outperformed the market over the past 10 years by 9.77% on an annualized basis producing an average annual return of 20.97%. Currently, Murphy USA has a market capitalization of $9.71 billion. 
Buying $100 In MUSA: If an investor had bought $100 of MUSA stock 10 years ago, it would be worth $665.09 today based on a price of $479.46 for MUSA at the time of writing.
<h3>Murphy USA's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739999709_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

MUSA

Here's How Much You Would Have Made Owning Murphy USA Stock In The Last 10 Years

Enovix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENVX#NASDAQ">ENVX</a>) is looking for Q1 Adj EPS of $(0.21)-$(0.15) vs $(0.18) analyst estimate. sees sales of $3.500 million-$5.500 million vs $6.17 million analyst estimate.

Enovix Sees Q1 Adj EPS $(0.21)-$(0.15) vs $(0.18) Est; Sees Sales $3.500M-$5.500M vs $6.17M Est

Herbalife Sees Q1 2025 Revenue (5.5%)-(1.5) YoY

On Wednesday, Bristol Myers Squibb&nbsp;&amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) announced the final analysis of overall survival (OS) from the Phase 3 CheckMate -816 study, which evaluated&nbsp;Opdivo (nivolumab) in combination with platinum-doublet chemotherapy as a neoadjuvant treatment for adult patients with resectable non-small <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43808682/bristol-myers-squibb-announces-opdivo-plus-chemotherapy-as-the-first-and-only-neoadjuvant-only-imm" rel="noreferrer noopener">cell lung cancer (NSCLC)</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/02/43774882/donald-trumps-tax-cut-could-add-46-trillion-to-deficit-says-robert-reich-emphasizing-48-billion-relief-for-top-100-us-firms-via-corporate-tax-cuts" rel="noreferrer noopener">Trump&#8217;s Tax Cut Could Add $4.6 Trillion To Deficit, With $48 Billion Tax Relief For Top 100 Firms: Robert Reich</a>
The results showed a statistically significant and clinically meaningful improvement in overall survival, a key secondary endpoint, compared to neoadjuvant chemotherapy alone.
The results build on the previously reported primary endpoints of event-free survival (EFS) and pathological complete response (pCR), which also met statistical significance.
The safety profile of&nbsp;Opdivo&nbsp;in combination with chemotherapy was consistent with previously reported studies, with no new safety signals observed.
&#8220;The final analysis of overall survival in the CheckMate -816 study underscores the potential of&nbsp;Opdivo&nbsp;in combination with chemotherapy to provide a meaningful survival benefit for patients with resectable NSCLC,&#8221; said Dana Walker, vice president, global program lead, late development, oncology, Bristol Myers Squibb. &#8220;This is the first and only Phase 3 study of a neoadjuvant-only immuno-oncology therapy to show a statistically significant benefit in patients with resectable NSCLC.&#8221;
In October, the FDA approved&nbsp;Bristol Myers&#8217; Opdivo for resectable NSCLC and no known epidermal growth factor&nbsp;receptor mutations or anaplastic lymphoma kinase (ALK) rearrangements, for neoadjuvant treatment, in combination with platinum-doublet chemotherapy,&nbsp;followed by single-agent&nbsp;Opdivo&nbsp;as adjuvant&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41184042/bristol-myers-10b-cancer-drug-opdivo-scores-expanded-use-fda-approval-for-lung-cancer-in-pre-and-" rel="noreferrer noopener">treatment after surgery</a>.
Last week, Bristol Myers released topline data from its Phase 2 TRANSCEND FL trial of&nbsp;Breyanzi&nbsp;(lisocabtagene maraleucel) for relapsed or refractory indolent B-cell&nbsp;<a target="_blank" href="https://www.benzinga.com/25/02/43597173/whats-going-on-with-bristol-myers-squibb-stock-on-monday" rel="noreferrer noopener">non-Hodgkin lymphoma</a>.
The study met its primary endpoint in the marginal zone lymphoma (MZL) cohort and Breyanzi&nbsp;demonstrated a statistically significant and clinically meaningful overall response rate (ORR) in these patients. It also met the key secondary endpoint of complete response rate (CRR).
Price Action: BMY stock closed higher by 1.01% to $54.98 on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43817229/nisun-international-partners-with-gold-of-china-aiming-30-50-million-gold-market-expansion-in-2025" target="_blank" rel="noreferrer noopener">Nisun Partners With Gold Of China To Tap Booming Market: Details</a></li>
</ul>
Photo via Shutterstock

Biotech

Health Care

Bristol Myers Cancer Drug Opdivo In Combination With Chemo Shows Improved Overall Survival In Certain Patients With Lung Cancer

Farmland Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FPI#NYSE">FPI</a>) reported quarterly earnings of $0.19 per share which beat the analyst consensus estimate of $0.17 by 11.76 percent. This is a 18.75 percent increase over earnings of $0.16 per share from the same period last year. The company reported quarterly sales of $21.47 million which beat the analyst consensus estimate of $20.29 million by 5.82 percent. This is a 0.55 percent decrease over sales of $21.59 million the same period last year.

First Trust Advantage Preferred Income Fund

Farmland Partners Q4 FFO $0.19 Beats $0.17 Estimate, Sales $21.47M Beat $20.29M Estimate

Pinstripes Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNST#NYSE">PNST</a>) reported quarterly losses of $(0.19) per share which missed the analyst consensus estimate of $(0.13) by 46.15 percent. This is a 157.58 percent decrease over earnings of $0.33 per share from the same period last year. The company reported quarterly sales of $35.516 million which missed the analyst consensus estimate of $36.350 million by 2.29 percent. This is a 10.43 percent increase over sales of $32.162 million the same period last year.

Earnings Misses

PNST

Pinstripes Holdings Q3 2025 GAAP EPS $(0.19) Misses $(0.13) Estimate, Sales $35.516M Miss $36.350M Estimate

IBIO

iBio To Begin Trading On Nasdaq On March 4, 2025 Under "IBIO"

Pulmonx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNG#NASDAQ">LUNG</a>) sees FY2025 sales of $96.000 million-$98.000 million vs $97.72 million analyst estimate.

LUNG

Pulmonx Sees FY2025 Sales $96.000M-$98.000M vs $97.72M Est

GRI's common stock is expected to begin trading on a post-split adjusted basis on February 24, 2025
LA JOLLA, CA, Feb. 19, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=MzcPI4Nne-gM9Y7IcrvoQNVonsr-sxSgaMIIl8GMorqA_B5Lg8fWbPdlBY6JIGy97U4a6Zc22KT2nbZICLkmUw==">GRI Bio, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRI#NASDAQ">GRI</a>) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovative pipeline of Natural Killer T ("NKT") cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that the board of directors of the Company approved a&nbsp;1-for-17 reverse stock split (the "Reverse Split") of the Company's common stock. The Reverse Split was approved by the stockholders of the Company at a special meeting of the Company held on February 11, 2025. The Reverse Split will legally take effect at 4:01 p.m. Eastern Time, on February 21, 2025. The Company's common stock will open for trading under a new CUSIP number 3622AW 403 on The Nasdaq Capital Market on February 24, 2025, on a split-adjusted basis under the current ticker symbol "GRI." The Reverse Split is intended to increase the per share trading price of the Company's common stock to enable the Company to regain compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market.

Stock Split

ALPS ETF Trusthen & Steers Global Realty Majors ETF

GRI Bio Announces 1-For-17 Reverse Stock Split, Expected To Begin Trading On A Post-Split Adjusted Basis On February 24, 2025

The company's SEMVision&#x2122; H20 system combines the industry's most sensitive electron beam (eBeam) technology with advanced AI image recognition to enable better and faster analysis of buried nanoscale defects in the world's most advanced chips.

AMAT

Applied Materials Unveils New Chip Defect Review System

Rogers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROG#NYSE">ROG</a>) is looking for Q1 GAAP EPS of $(0.26)-$0.04 vs $0.72 analyst estimate..

Rogers Sees Q1 GAAP EPS $(0.26)-$0.04 vs $0.72 Est

WIIM

INSG

Inseego shares are trading lower. The company reported Q4 financial results.

Rogers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROG#NYSE">ROG</a>) is looking for Q1 Adj EPS of $0.10-$0.40 vs $0.72 analyst estimate. sees sales of $180.000 million-$195.000 million vs $200.20 million analyst estimate.

Rogers Sees Q1 Adj EPS $0.10-$0.40 vs $0.72 Est; Sees Sales $180.000M-$195.000M vs $200.20M Est

Broadstone Net Lease Sees FY25 AFFO $1.45-$1.49 Vs $1.52 Est.

Enovix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENVX#NASDAQ">ENVX</a>) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.18) by 38.89 percent. This is a 60.71 percent increase over losses of $(0.28) per share from the same period last year. The company reported quarterly sales of $9.72 million which beat the analyst consensus estimate of $8.77 million by 10.79 percent. This is a 31.65 percent increase over sales of $7.38 million the same period last year.

Enovix Q4 Adj EPS $(0.11) Beats $(0.18) Estimate, Sales $9.72M Beat $8.77M Estimate

ServiceNow, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>) shares are trading higher on Monday. The company plans to invest $1.5 billion in the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/b41309948/servicenow-pledges-1-5bn-investment-into-uk-business-over-five-years" rel="noreferrer noopener">U.K. over the next five years</a>.



The company plans to expand office space and increase its workforce beyond 1,000 employees.



The investment will also enhance its London and Newport data centers with Nvidia GPUs for local LLM data processing and introduce skills programs for 240,000 U.K. learners.



ServiceNow is reaffirming its commitment to the U.K. by investing in expanded office space, significant workforce growth, and AI skills programs.



The company aims to leverage AI through domain-specific LLMs in U.K. data centers and to provide reskilling opportunities for British workers.



ServiceNow Chairman and CEO Bill McDermott&nbsp;said,&nbsp;&#8220;The United Kingdom is embracing technology transformation at scale. In this new age of AI, the country continues to be a global leader in driving innovation for the benefit of all its communities.&#8221;



&#8220;Our investment accelerates the UK&#8217;s push to put AI to work, empowering people, enriching experiences, and strengthening societal bonds. Together, ServiceNow and our customers across the UK are delivering a future where technology benefits everyone.&#8221;



Investors can gain exposure to the stock via&nbsp;iShares Expanded Tech-Software Sector ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/IGV#BATS">IGV</a>) and Franklin Exponential Data ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/XDAT#BATS">XDAT</a>).



Price Action: NOW shares are up 0.71% at $945.25 at the last check on Monday.



Image via Shutterstock



Read Next:



<ul>
<li><a href="https://www.benzinga.com//node/41309943" target="_blank" rel="noreferrer noopener">Nasdaq, S&amp;P 500 Futures Rise Solidly Ahead Of Q3 Earnings Season, Boeing Drags Dow: This Strategist Sees &#8216;A Lot Of Firepower&#8217; Supporting Market After Election</a></li>
</ul>

ServiceNow, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>) shares are rising in premarket trading on Thursday following its <a target="_blank" href="https://www.benzinga.com/premarket" rel="noreferrer noopener">second-quarter earnings report, which exceeded analysts&#8217; expectations.</a>



The company&nbsp;reported second-quarter revenue of $2.627 billion, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus estimate</a> of $2.607 billion<a target="_blank" href="https://www.benzinga.com/pressreleases/24/07/b39942290/servicenow-reports-second-quarter-2024-financial-results" rel="noreferrer noopener">, per a press release.</a>



Analysts anticipate that robust U.S. federal business and increasing adoption of AI software will counterbalance the impact of economic uncertainty on the company, <a target="_blank" href="https://www.cnbc.com/2024/07/24/servicenow-raises-annual-subscription-revenue-forecast-on-robust-demand-coo-resigning-after-government-contract-complaint-.html" rel="noreferrer noopener">reported </a>CNBC.



According to&nbsp;<a target="_blank" href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" rel="noreferrer noopener">Benzinga Pro</a>, NOW stock has gained over 25% in the past year. Investors can gain exposure to the stock via&nbsp;Franklin Exponential Data ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/XDAT#BATS">XDAT</a>) and Franklin Exponential Data ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/IGV#BATS">IGV</a>).



Also Read: <a target="_blank" href="https://www.benzinga.com/news/earnings/24/07/39944577/servicenow-q2-earnings-revenue-beat-eps-beat-servicenow-intends-to-reinvent-every-workflow-in-every" rel="noreferrer noopener">ServiceNow Q2 Earnings: Revenue Beat, EPS Beat — &#8216;ServiceNow Intends To Reinvent Every Workflow, In Every Company, In Every Industry With GenAI&#8217;</a>



Meanwhile, ServiceNow disclosed the immediate departure of President and Chief Operating Officer CJ Desai following an investigation into the hiring of a former U.S. Army technology leader. However, the company assured that the hiring issue was a singular incident.



Earlier, ServiceNow also announced that it acquired&nbsp;Raytion, a Germany-based information retrieval technology provider.



NNACV for Now Assist, ServiceNow&#8217;s GenAI experience, doubled quarter over quarter and surpassed expectations significantly, with 11 deals exceeding $1 million in the quarter.



In an interview, Chief Executive Officer Bill McDermott highlighted that the adoption of the company&#8217;s generative AI-oriented products is contributing significantly to the increase in earnings. McDermott stated, &#8220;I doubt you could have had these extraordinary results without generative AI,&#8221; <a target="_blank" href="https://www.bloomberg.com/news/articles/2024-07-24/servicenow-reports-strong-sales-on-expanded-product-line?sref=TBDibEcD" rel="noreferrer noopener">reported </a>Bloomberg.



ServiceNow expects third-quarter subscription revenue of $2.66 billion to $2.665 billion, representing growth of 20% to 20.5% on a year-over-year basis.&nbsp;



ServiceNow&#8217;s expansion of its product line has positioned it in more direct competition with peers like Salesforce, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) and Workday, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDAY#NASDAQ">WDAY</a>).



McDermott emphasized that ServiceNow is experiencing significant improvement in their customer service and employee-oriented solutions, which directly compete with offerings from Salesforce and Workday, Bloomberg added.



Price Action: NOW shares are trading higher by 6.04% to $775.00&nbsp;premarket at last check Thursday.



Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.



Image: Shutterstock



Read Next:



<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/07/39945781/meta-cracks-down-on-nigerian-yahoo-boys-in-massive-sextortion-scam-purge-bans-63k-accounts" target="_blank" rel="noreferrer noopener">Meta Cracks Down On Nigerian &#8216;Yahoo Boys&#8217; In Massive Sextortion Scam Purge, Bans 63K Accounts</a></li>
</ul>

Comments

Franklin Exponential Data ETF

News

Latest news for Franklin Exponential Data ETF (BATS:XDAT)

Monday, October 14, 2024

Thursday, July 25, 2024

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga